World Journal of Oncology · 2020 · 19 citations · 8 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyMedical OncologyCancer ImmunotherapyCheckpoint Inhibitor TherapyCombination ImmunotherapyImmune Checkpoint InhibitorsImmunotherapy Response AssessmentPartial Response AssessmentPd-l1 BlockadePembrolizumab TherapyProgrammed Cell Death Protein 1 InhibitorsProgrammed Death-1 BlockadeProgrammed Death-1 InhibitionProgrammed Death-ligand 1 Inhibitors
BACKGROUND: Immunotherapy agents offer novel treatment options in advanced cancers. However, their use is limited in developing countries lacking unifying guidelines and can be followed by a financial burden. In this study, we aimed to provide an overview regarding the use of immunotherapy and the overall response to treatment in patients with metastatic disease in relation to cost-effectiveness. METHODS: This was a retrospective study involving adult metastatic cancer patients, treated with programmed cell death-1 (PD-1) inhibitors at American University of Beirut Medical Center (AUBMC), a tertiary cancer center in Lebanon. Study enrollment began on January 1, 2014 and ended on January 12, 2016. Baseline demographics, epidemiological and clinical data were collected from the patients' records. RESULTS: Our study consisted of 34 patients. Fifteen patients self-financed the treatment. The patients were prescribed immunotherapy without programmed cell death-ligand 1 (PD-L1) testing as it was not part of the guidelines at the time. Twenty-two patients were treated with nivolumab and 12 patients with pembrolizumab. Thirteen patients showed partial response or stable disease, while 21 patients showed progression. CONCLUSION: Improvement in terms of overall survival and progression-free survival has been undercut by the lack of availability of these drugs and their cost. Considering that a large percentage of patients do not respond to immunotherapy, there is a need to use guidelines such as a preset PD-L1 level that ensure cost-effectiveness and prevent resource waste.
8
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text
Medicine, Oncology, Pharmacology +17
Pembrolizumab for the treatment of non-small cell lung cancer
Sung Hee Lim, Jong‐Mu Sun, Se‐Hoon Lee et al. · Expert Opinion on Biological Therapy · 2016 · 289 citations
Medicine, Oncology, Pharmacotherapy +17
Cancer Immunotherapy, Part 3: Challenges and Future Trends.
PubMed · 2017 · 261 citations · Full text
Life Sciences, Immunology, Oncology +17